



UNITED STATES PATENT AND TRADEMARK OFFICE

cl

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/052,824	11/07/2001	Fernand Labrie	P/1259-636	4181
2352	7590	06/27/2005	EXAMINER	
OSTROLENK FABER GERB & SOFFEN 1180 AVENUE OF THE AMERICAS NEW YORK, NY 100368403			JIANG, SHAOJIA A	
			ART UNIT	PAPER NUMBER
			1617	

DATE MAILED: 06/27/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/052,824

Applicant(s)

LABRIE, FERNAND

Examiner

Shaojia A. Jiang

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 21 April 2005.
2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-28 is/are pending in the application.
4a) Of the above claim(s) 7-12 is/are withdrawn from consideration.
5) ☐ Claim(s) _____ is/are allowed.
6) ☒ Claim(s) 1-6 and 13-28 is/are rejected.
7) ☐ Claim(s) _____ is/are objected to.
8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____
4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____

DETAILED ACTION

This Office Action is in response to Applicant's response (remarks/Arguments) filed on April 21, 2005.

Currently, claims 1-28 are pending in this application.

Note that Applicant's election without traverse of the species of EM-652.HCl in claim 17 for the SERM compound, 17 β -estradiol in claim 20 for as an estrogen, and dehydroepiandrosterone (DHEA) for additional agent in claim 2, submitted April 30, 2002 has been recorded in the previous Office Action May 21, 2002.

As indicated in the previous Office Action dated November 18, 2004, claims 7-12 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. The claims have been examined insofar as they read on the elected specie.

Claims 1-6 and 13-28 are currently under examination on the merits.

Applicant's remarks filed April 21, 2005 regarding that the Restriction Requirement made in the parent case, 09/771180 to both 10/143894 and the instant case, with respect to the provisional rejection made under the judicially created doctrine of obviousness-type double patenting rejection Claims 1-6 and 13-28 over claims 1-2, 4-6, 12-21, 24-27, 34-43 and 45-48 of the copending Application 10/143894 of record stated in the Office Action November 18, 2004 have been considered and are found persuasive to remove this particular rejection. Therefore, the said rejection is withdrawn.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-6 and 21-28 are rejected under 35 U.S.C. 112, first paragraph, for scope of enablement because the specification, while being enabling for the particular selective estrogen receptor modulator (SERM) compounds having the formula in claims 13-20 herein and the particular estrogens in claims 20-21, further in combination with the particular additional agent such as DHEA in the claimed methods herein, does not reasonably provide enablement for any selective estrogen receptor modulator and any estrogens and any androgenic agents, encompassed by the claims herein, for the same reasons of record in the previous Office Action November 18, 2004.

The recitations, "one selective estrogen receptor modulator", "one estrogen", and "an androgenic agent" are seen to be merely functional language.

Even regarding the recitation for compounds in claims 4-5, one skilled in the art would clearly recognize that the recitation would encompass numerous compounds containing various structurally different substituents.

The instant specification fails to provide information that would allow the skilled artisan to fully practice the instant invention without ***undue experimentation***. Attention is directed to *In re Wands*, 8 USPQ2d 1400 (CAFC 1988) at 1404 where the court set forth the eight factors to consider when assessing if a disclosure would have required

Art Unit: 1617

undue experimentation. Citing *Ex parte Forman*, 230 USPQ 546 (BdApls 1986) at 547 the court recited eight factors:

(1) the nature of the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary.

The nature of the invention: The instant invention pertains to the methods for the therapeutic treatments for menopausal patients.

The relative skill of those in the art: The relative skill of those in the art is high.

The breadth of the claims: The instant claims are deemed very broad since the broadest claims (i.e., claims 1-2) reads on any “selective estrogen receptor modulator” and “estrogen” and any “androgenic agent” encompassed by the claims herein.

The amount of direction or guidance presented:

Functional language at the point of novelty, as herein employed by Applicants, is admonished in *University of California v. Eli Lilly and Co.* 43 USPQ2d 1398 (CAFC, 1997) at 1406: stating this usage does “little more than outline goal appellants hope the recited invention achieves and the problems the invention will hopefully ameliorate”. The CAFC further clearly states that “[A] written description of an invention involving a chemical genus, like a description of a chemical species, requires a precise definition, such as by structure, formula, [or] chemical name, of the claimed subject matter sufficient to distinguish it from other materials” at 1405(emphasis added), and that “It does not define any structural features commonly possessed by members of the genus

that distinguish from others. One skilled in the art therefore cannot, as one can do with a fully described genus, visualize or recognize the identity of the members of the genus. A definition by function, as we have previously indicated, does not suffice to define the genus.." at 1406 (emphases added).

In the instant case, "one selective estrogen receptor modulator", "one estrogen", and "an androgenic agent" recited in the instant claims are purely functional distinction. Hence, these functional recitations read on any compounds that might have the recited functions. However, the specification merely provides those particular compounds for each kind of functional compounds for the composition in claims.

Thus, Applicants functional language at the points of novelty fails to meet the requirements set forth under 35 U.S.C. 112, first paragraph. Claims employing functional language at the exact point of novelty, such as Applicants', neither provide those elements required to practice the inventions, nor "inform the public during the life of the patent of the limited of monopoly asserted" (*General Electric Company v. Wabash Appliance Corporation et al.* 37 USPQ at 468 (US Supreme Court 1938)).

The predictability or unpredictability: the instant claimed invention is highly *unpredictable* as discussed below:

It is noted that the pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. *In re Fisher*, 427 F.2d 833, 166 USPQ 18 (CCPA 1970) indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute. In the instant case, the instant claimed invention is highly unpredictable since one skilled in the art

Art Unit: 1617

cannot fully described genus, visualize or recognize the identity of the members of the genus, by structure, formula, or chemical name, of the claimed subject matter, as discussed above in *University of California v. Eli Lilly and Co.* Hence, in the absence of fully recognizing the identity of the members genus herein, one of skill in the art would be unable to fully predict possible physiological activities of any compounds having claimed functional properties in the pharmaceutical compositions herein.

Moreover, one of skill in the art would recognize that it is highly unpredictable in regard to therapeutic effects, side effects, and especially serious toxicity that may be generated by drug-drug interactions when and/or after administering to a host (e.g., a human) the **combination** of any compounds represented by “one selective estrogen receptor modulator”, “one estrogen”, and “an androgenic agent”. See text book “Goodman & Gilman's The Pharmacological Basis of Therapeutics” regarding possible drug-drug interactions (9th ed, 1996) page 51 in particular. This book teaches that “The frequency of significant beneficial or adverse drug interactions is unknown” (see the bottom of the left column of page 51) and that “Recognition of beneficial effects and recognition of and prevention of adverse drug interactions require a thorough knowledge of the intended and possible effects of drugs that are prescribed” and that “The most important adverse drug-drug interactions occur with drugs that have serious toxicity and a low therapeutic index, such that relatively small changes in drug level can have significant adverse consequences” (see the right column of page 51) (emphases added). In the instant case, in the absence of fully recognizing the identity of the members genus herein, one of skill in the art would not be able to fully predict possible

Art Unit: 1617

adverse drug-drug interactions occurring with many combinations of any compounds having claimed functional properties in the pharmaceutical compositions herein to be administered to a host. Thus, the teachings of the book clearly support that the instant claimed invention is highly unpredictable.

Further, any compounds represented by “one selective estrogen receptor modulator”, “one estrogen”, and “an androgenic agent” may reasonably encompass those known and unknown three classes functional compounds as of the instant filing date, especially those future known selective estrogen receptor modulators and estrogens and androgenic agent. As a result, additional or future research to establish or verify their usefulness must be required.

Therefore, to practice the claimed invention herein, a person of skill in the art would have to exercise undue experimentation to test all compounds encompassed in the instant claims.

The presence or absence of working examples and the quantity of experimentation necessary:

As discussed above, only those particular compound for each kind of functional compounds employed in the composition herein is disclosed in the specification. Moreover, it is noted that the specification merely provides the testing of two particular SERMs (i.e., EM-652 and EM-800) in working examples of the instant specification. Thus, the evidence in the examples is also not commensurate in scope with the claimed invention and does not demonstrate criticality of a claimed range of the compounds in the claimed composition.

Thus, the specification fails to provide sufficient support of the broad use of any compounds having those functions recited in the instant claims. As a result, necessitating one of skill to perform an exhaustive search for the embodiments of any compounds having those functions recited in the instant claims suitable to practice the claimed invention.

Genentech, 108 F.3d at 1366, states that “a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion” and “[p]atent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable”.

Therefore, in view of the Wands factors, the case *University of California v. Eli Lilly and Co.* (CAFC, 1997) and *In re Fisher* (CCPA 1970) discussed above, to practice the claimed invention herein, a person of skill in the art would have to engage in undue experimentation to test all compounds encompassed in the instant claims and their combinations employed in the claimed compositions to be administered to a host, with no assurance of success.

Response to Argument

Applicant's arguments filed April 21, 2005 with respect to this rejection made under 35 U.S.C. 112, first paragraph, for lack of full scope of enablement have been fully considered but are not deemed persuasive as further discussed below.

Applicant argues that “selective estrogen receptor modulators”, “estrogens”, and “androgens” are well-defined in the art, and represent a classes of compounds whose

members are expected to behave similarly. Applicant arguments have been considered but not found convincing.

In this case, the instant claims are not limited to those particular known “selective estrogen receptor modulators”, “estrogens”, and “androgens”.

These functional recitations may reasonably encompass those known and unknown or future known compounds having the recited functions as of the instant filing date. Note that those future known compounds have not yet been discovered and/or made as of the instant filing date. Hence, those unknown or future known compounds encompassed by claim 1 herein **must** require to additional or future research to discover, establish, make and/or verify their usefulness. Therefore, as indicated in the previous Office Action, the skilled artisan has to exercise **undue experimentation** to practice the instant invention.

Moreover, the instant claims read on administering to a patient the **combination** of any compounds represented by “one selective estrogen receptor modulator”, “one estrogen”, and “an androgenic agent”. Thus, in the absence of fully recognizing the identity of the members genus herein, one of skill in the art would not be able to fully predict possible adverse drug-drug interactions occurring with many combinations of any compounds having claimed functional properties in the pharmaceutical compositions herein to be administered to a host as discussed in the previous Office Action. Thus, the instant claimed invention is highly unpredictable.

Further, it is noted that the specification merely provides the testing of two particular SERMs (i.e., EM-652 and EM-800) in working examples of the instant

specification. Thus, the evidence in the examples is also not commensurate in scope with the claimed invention and does not demonstrate criticality of a claimed range of the compounds in the claimed composition as discussed in the previous Office Action.

For the above stated reasons, said claims are properly rejected made under 35 U.S.C. 112, first paragraph, for lack of full scope of enablement.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-6 and 23-28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for the same reasons of record in the previous Office Action November 18, 2004.

The recitations, "derivative" and "derivatives" in the claims render claims 1-6 and 23-28 indefinite. The recitations, "derivative" and "derivatives" are not defined in the specification. Hence, one of ordinary skill in the art could not interpret the metes and bounds as to "derivative" and "derivatives", in the claim. Therefore, the scope of claim is indefinite as to the composition encompassed thereby.

Response to Argument

Applicant's arguments filed April 21, 2005 with respect to this rejection made under 35 U.S.C. 112, second paragraph, for indefinite recitations, "derivative" and

"derivatives" have been fully considered but are not deemed persuasive as further discussed below.

Applicant argues that "derivative" is well-known to encompass having a particular basic structure. Applicant arguments have been considered but not found convincing. One of ordinary skill in the art could not ascertain and interpret the metes and bounds of the patent protection desired as to "derivative" of compounds herein, since one of ordinary skill in the art would clearly recognize that since one of ordinary skill in the art would clearly recognize that "derivative" would read on any compounds of the formula herein having any widely varying groups and possibly substituting groups.

Note that exemplification or some specific derivatives herein is not explicit definition of a general term "derivative". Given the fact that any significant structural variation to a compound would be reasonably expected to alter its properties, e.g., physical, chemical, physiological effects and functions. Thus, it is unclear and indefinite as to the "derivative" of compounds herein encompassed thereby.

For the above stated reasons, said claims are properly rejected made under 35 U.S.C. 112, second paragraph.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 3-6 and 13-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Labrie (5,362,720), and Labrie et al. (WO 96/26201), and Applicant's admission regarding the prior art in the specification at 2 lines 3-4, for the same reasons of record in the previous Office Action November 18, 2004.

Labrie (5,362,720) teaches that estrogens such as 17 β -estradiol are well known to be used in estrogen therapy in menopausal women. However, estrogens are known to induce estrogen-dependent diseases such as breast cancer. Labrie also discloses that androgenic compounds or androgenic steroids are useful in methods of treating or preventing estrogen-dependent diseases such as breast cancer. See abstract, col.1 line 35-38, col.4 lines 45-48, col.10, and claims 1-30.

Labrie et al. (WO 96/26201) discloses that the particular SERM, EM-652 (the instant elected species) or its pharmaceutically acceptable salts such as EM-652.HCl, have anti-estrogen activities and are therefore useful in methods of treating estrogen sensitive or estrogen-dependent diseases such as breast cancer, which is known estrogen-induced effects. See abstract, page 1, page 6-8, 10, and 19-21, and claims 11-12.

Applicant's admission regarding the prior art in the specification at 2 lines 3-4 teaches that Hormone Replace Therapy (e.g., administration of estrogens) is known to be useful in treatment of menopausal symptoms.

The prior art does not expressly disclose the employment of the combination of an estrogen such as 17 β -estradiol and the particular SERM, EM-652.HCl, or maybe

further combining an androgenic compound in a method of reducing or eliminating the incidence of menopausal symptoms.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to employ of the combination of an estrogen such as 17β -estradiol and the particular SERM, EM-652.HCl, or to further combine an androgenic compound in a method of reducing or eliminating the incidence of menopausal symptoms.

One having ordinary skill in the art at the time the invention was made would have been motivated to employ the combination of an estrogen such as 17β -estradiol and the particular SERM, EM-652.HCl, or to further combine an androgenic compound in a method of reducing or eliminating the incidence of menopausal symptoms, since estrogens such as 17β -estradiol is well known in the art to be used in estrogen therapy or Hormone Replace Therapy in menopausal women for reducing or eliminating the incidence of menopausal symptoms.

Moreover, 17β -estradiol in combination with androgenic compounds or androgenic steroids is known to be capable to inhibiting breast tumor or cancer growth, and are therefore useful in methods of treating estrogen-dependent diseases, e.g., breast cancer according to Labrie. Further, the particular SERM, EM-652.HCl, is known to be in methods of treating estrogen-dependent diseases. Therefore, one of ordinary skill in the art would have reasonably expected that combining an estrogen such as 17β -estradiol and the particular SERM, EM-652.HCl, or further combining an androgenic compound would be useful in reducing or eliminating the incidence of menopausal symptoms, while reducing the risk of or treating estrogen-dependent

diseases such as breast cancer induced by estrogens during estrogen therapy in menopausal women for reducing or eliminating the incidence of menopausal symptoms, since each of components herein is known to be useful in the same treatment, i.e., treating estrogen-dependent diseases.

Since all active composition components herein are known to be useful to reduce or treat estrogen-dependent diseases, it is considered prima facie obvious to combine them into a single composition to form a third composition useful for the very same purpose. At least additive therapeutic effects would have been reasonably expected. See *In re Kerkhoven*, 205 USPQ 1069 (CCPA 1980).

Thus the claimed invention as a whole is clearly prima facie obvious over the teachings of the prior art.

Response to Argument

Applicant's arguments filed April 21, 2005 with respect to this rejection made under 35 U.S.C. 103(a) of record in the previous Office Action November 18, 2005 have been fully considered but are not deemed persuasive as to the nonobviousness of the claimed invention over the prior art as further discussed below.

Applicant asserts that [a]t most, the Examiner's proposed combination of references imposes an improper "obvious to try" standard. But even if it were shown that applicant's procedures were "obvious to try", the references did not show that there was a reasonable expectation of success". In contrast to applicant's assertion of the rejection is based upon an "obvious-to-try" standard; it is by now well understood that the ultimate conclusion of law that claimed subject matter as a whole would have been

Art Unit: 1617

obvious under 35 USC 103 may at times properly be drawn from an inference of fact arising from prior art teachings which could be considered an inference that it would be "obvious to try" that which is claimed. In re O'Farrell, 853 F.2d 894, 7 USPQ 2d 1973 (Fed. Cir. 1988); Contour Saws Inc. v. Starrett Co., 444 F. 2d 433, 170 USPQ 433 (Ct.App. 1977); In re Marzocchi, 439 F. 2d 220, 169 USPQ 367 (CCPA 1977); In re Lindell, 385 F. 2d 435, 155 USPQ 521 (CCPA 1967).

In the instant case, as discussed in the previous Office Action, one having ordinary skill in the art at the time the invention was made would have been motivated to employ the combination of an estrogen such as 17 β -estradiol and the particular SERM, EM-652.HCl, or to further combine an androgenic compound in a method of reducing or eliminating the incidence of menopausal symptoms, since estrogens such as 17 β -estradiol is well known in the art to be used in estrogen therapy or Hormone Replace Therapy in menopausal women for reducing or eliminating the incidence of menopausal symptoms.

Moreover, 17 β -estradiol in combination with androgenic compounds or androgenic steroids is known to be capable to inhibiting breast tumor or cancer growth, and are therefore useful in methods of treating estrogen-dependent diseases, e.g., breast cancer according to Labrie. Further, the particular SERM, EM-652.HCl, is known to be in methods of treating estrogen-dependent diseases. Therefore, one of ordinary skill in the art would have reasonably expected that combining an estrogen such as 17 β -estradiol and the particular SERM, EM-652.HCl, or further combining an androgenic compound would be useful in reducing or eliminating the incidence of

menopausal symptoms, while reducing the risk of or treating estrogen-dependent diseases such as breast cancer induced by estrogens during estrogen therapy in menopausal women for reducing or eliminating the incidence of menopausal symptoms, since each of components herein is known to be useful in the same treatment, i.e., treating estrogen-dependent diseases.

Applicant argues that Labrie et al. (WO 96/26201) at page 5 lines 2-3 does not teach for treating menopausal women patients. However, the patient population who suffer the estrogen-related diseases such as breast cancer, uterine cancer, and ovarian cancer, during estrogen therapy disclosed by (WO 96/26201) at page 5 the 3rd paragraph, is well known to encompass menopausal woman patients.

Applicant also argues that the estrogen-related diseases such as breast cancer, uterine cancer, and ovarian cancer, are well-known to respond adversely to estrogens. Nonetheless, patients taught in WO 96/26201 were undergoing estrogen therapy by administering estrogen. That is the object of the invention therein to provide EM-652, the instant compound having anti-estrogen activity to treat estrogen sensitive or estrogen-dependent diseases such as breast cancer. Hence, WO 96/26201 has clearly provided the motivation for the instant claimed invention.

Therefore, motivation to combine the teachings of the prior art cited herein to make the present invention is seen. The claimed invention is clearly obvious in view of the prior art.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Labrie (5,362,720), and Labrie (5,780,460, PTO-892), and Labrie et al. (WO 96/26201), and Applicant's admission regarding the prior art in the specification at 2 lines 3-4 for the same reasons of record in the previous Office Action dated November 18, 2004.

Labrie (5,362,720) teaches that estrogens such as 17 β -estradiol are well known to be used in estrogen therapy in menopausal women. However, estrogens are known to induce estrogen-dependent diseases such as breast cancer. Labrie also discloses that androgenic compounds or androgenic steroids are useful in methods of treating or preventing estrogen-dependent diseases such as breast cancer. See abstract, col.1 line 35-38, col.4 lines 45-48, col.10, and claims 1-30.

Labrie (5,780,460) discloses that sex steroid precursors such as DEHA alone or in combination with an estrogen are useful in method of reducing or eliminating the incidence of menopausal symptoms, e.g., vaginal atrophy and diminished libido, and also useful in methods of treating or preventing estrogen-dependent diseases such as breast cancer. See abstract, col. 1-2, col.3 lines 44-55, and claims 1-2.

Labrie et al. (WO 96/26201) discloses that the particular SERM, EM-652 (the instant elected species) or its pharmaceutically acceptable salts such as EM-652.HCl,

Art Unit: 1617

have anti-estrogen activities and are therefore useful in methods of treating estrogen sensitive or estrogen-dependent diseases such as breast cancer, which is known estrogen-induced effects. See abstract, page 1, page 6-8, 10, and 19-21, and claims 11-12.

Applicant's admission regarding the prior art in the specification at 2 lines 3-4 teaches that Hormone Replace Therapy (e.g., administration of estrogens) is known to be useful in treatment of menopausal symptoms.

The prior art does not expressly disclose the employment of the combination of an estrogen such as 17β -estradiol and the particular SERM, EM-652.HCl, and DHEA in a method of reducing or eliminating the incidence of menopausal symptoms.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to employ of the combination of an estrogen such as 17β -estradiol and the particular SERM, EM-652.HCl, and DHEA in a method of reducing or eliminating the incidence of menopausal symptoms.

One having ordinary skill in the art at the time the invention was made would have been motivated to employ the combination of an estrogen such as 17β -estradiol and the particular SERM, EM-652.HCl, and DHEA in a method of reducing or eliminating the incidence of menopausal symptoms, since estrogens such as 17β -estradiol are well known in the art to be used in estrogen therapy or Hormone Replace Therapy in menopausal women for reducing or eliminating the incidence of menopausal symptoms. Moreover, sex steroid precursors such as DEHA alone or in combination with an estrogen (e.g., 17β -estradiol) is known to be useful in method of reducing or

Art Unit: 1617

eliminating the incidence of menopausal symptoms, and also useful in methods of treating or preventing estrogen-dependent diseases such as breast cancer according to Labrie. Androgenic compounds are also known to be useful in methods of treating estrogen-dependent diseases. Further, the particular SERM, EM-652.HCl, is known to be in methods of treating estrogen-dependent diseases.

Therefore, one of ordinary skill in the art would have reasonably expected that combining an estrogen such as 17β -estradiol and the particular SERM, EM-652.HCl, and DHEA, or further combining an androgenic compound would be useful in reducing or eliminating the incidence of menopausal symptoms, while reducing the risk of or treating estrogen-dependent diseases such as breast cancer induced by estrogens during estrogen therapy in menopausal women for reducing or eliminating the incidence of menopausal symptoms, since each of components herein is known to be useful in the same treatment, i.e., treating estrogen-dependent diseases.

Since all active composition components herein are known to be useful to reduce or treat estrogen-dependent diseases, it is considered prima facie obvious to combine them into a single composition to form a third composition useful for the very same purpose. At least additive therapeutic effects would have been reasonably expected. See *In re Kerkhoven*, 205 USPQ 1069 (CCPA 1980).

Thus the claimed invention as a whole is clearly prima facie obvious over the teachings of the prior art.

Applicant's similar arguments filed April 21, 2005 with respect to this rejection made under 35 U.S.C. 103(a) of record in the previous Office Action have been fully

considered but are not deemed persuasive as adequately addressed by the first 103(a) obvious rejection presented above.

Further, as discussed in the previous Office Action, Applicant's testing results in Example 1-2 and 4-5 of the specification at pages 42-53 and 60-73 have been fully considered with respect to the nonobviousness and/or unexpected results of the claimed invention but are not deemed persuasive for the following reasons. The results herein are not seen to provide clear and convincing evidence of nonobviousness or unexpected results over the cited prior art for the combination of 17 β -estradiol and EM-652.HCl, or the combination of 17 β -estradiol and EM-652.HCl and DHEA in the claimed method of reducing or eliminating the incidence of menopausal symptoms. The specification provides **no side-by-side comparison with the closest prior art.**

Moreover, the testing herein is merely in the treatment of bone loss, a single menopausal symptom, in female rats, (see page 68-69). Thus, the evidence in the testing on is not commensurate in scope with the claimed invention and does not demonstrate criticality of a claimed broad range of menopausal symptoms herein. See MPEP § 716.02(d). Additionally, the tests herein merely employ two particular SERMs (i.e., EM-652 and EM-800), particular estrogens, and particular androgenic agents. Again, the evidence in the testing is not commensurate in scope with the claimed invention and does not demonstrate criticality of the claimed range of active agents herein in the claimed method. Further, the specification provides no evidence for treating menopausal women.

Art Unit: 1617

Therefore, no clear and convincing evidence of nonobviousness or unexpected results for the combination in the claimed method presented in specification herein is seen to support the nonobviousness of the instant claimed invention over the prior art.

For the above stated reasons, said claims are properly rejected under 35 U.S.C. 103(a).

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-6, and 13-28 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 14 of U.S. Patent No. 6,670,346.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the patent is drawn to a method of treating or reducing the risk of breast cancer and osteoporosis in a patient in need of said treatment comprising the same SERM or structurally substantially similar SERM herein and DHEA. The patent also discloses patients therein could also undergo Hormone Replace Therapy (e.g.,

administration of estrogens). It is noted that the transitional phrases "comprising" is employed in the method of the patent. Note that the transitional term "comprising" is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. See MPEP 2111.03.

The claim of the instant application is drawn to methods of reducing or eliminating the incidence of menopausal symptoms comprising administering the same SERM, estrogen and DHEA to menopausal patients. As discussed above, the patients in the patent are seen to encompass the menopausal patients in the instant application who is well known to have breast cancer and osteoporosis.

Thus, the instant claims 1-6, and 13-28 are seen to be obvious over the claims 1 and 14 of U.S. Patent No. 6,670,346.

Claims 1-6, and 13-28 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-2, 8-11, and 19-28 of U.S. Patent No. 6,465,445.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the patent is drawn to a method of treating or reducing the risk of breast cancer and osteoporosis in a patient in need of said treatment **comprising** the same SERM or structurally substantially similar SERM herein and DHEA. The patent also discloses patients therein could also undergo Hormone Replace Therapy (e.g., administration of estrogens). It is noted that the transitional phrases "comprising" is employed in the method of the patent. Note that the transitional term "comprising" is

inclusive or open-ended and does not exclude additional, unrecited elements or method steps. See MPEP 2111.03.

The claim of the instant application is drawn to methods of reducing or eliminating the incidence of menopausal symptoms comprising administering the same SERM, estrogen and DHEA to menopausal patients. As discussed above, the patients in the patent are seen to encompass the menopausal patients in the instant application who is well known to have breast cancer and osteoporosis.

Thus, the instant claims 1-6, and 13-28 are seen to be obvious over the claims 1-2, 8-11, and 19-28 of U.S. Patent No. 6,465,445.

Response to Argument

Applicant's arguments filed April 21, 2005 with respect to these rejections made under the judicially created doctrine of obviousness-type double patenting have been fully considered but are not deemed persuasive. Applicant asserts that the patents' methods comprising DHEA while the present invention requires estrogen. Contrary to Applicant's assertion, the instant claim 2 also requires DHEA.

Moreover, the patents 6,465,445 and 6,670,346 also disclose patients therein could also undergo Hormone Replace Therapy (e.g., administration of estrogens). It is noted that the transitional phrases "comprising" is employed in the method of the patent. Note that the transitional term "comprising" is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. See MPEP 2111.03.

For the above stated reasons, said claims are properly rejected made under the judicially created doctrine of obviousness-type double patenting.

In view of the rejections to the pending claims set forth above, no claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Jiang, whose telephone number is (571)272-0627. The examiner can normally be reached on Monday-Friday from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, Ph.D., can be reached on (571)272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



S. Anna Jiang, Ph.D.
Primary Examiner
Art Unit 1617
June 20, 2005